The proposed patent is a method of immunotherapy wherein unique and novel sources of antigen generating organisms/viruses/cells are incubated or electroporated into further novel immunogenic cells. This method may be used for cancer therapy or therapy of benign disease. This method may also be used for immunization from infectious organisms such as bacteria, fungi, viruses or parasites. An aliquot of cells or materials obtained from the antigen generating component or electroporated immunogenic cells may be preserved long-term (i.e. cryopreservation or lyophilization or desiccation) for the purpose of forming a library or archive for future therapy or drug development/research.Most importantly non-obviousness of this patent is clearly elucidated in the proposed method of immunotherapy whereby cancer stem cells (either directly isolated in culture or created by an induced process like iPSCs) are lysed for their protein antigens and electroporated or incubated with novel immunogenic cells (not dendritic cells) such as SVF and given back to the same patient in an autologous and personalized fashion. (In this way both MHC I and MHC II pathways may be utilized and a plurality of non-dendritic cells with antigen presenting capabilities are advantageously used in a plural immune like fashion raising immunogenicity through multiple novel and unique epitopes.
